US 11,951,147 B2
SMAC mimetic
Stephen M. Condon, Glenmoore, PA (US); Yijun Deng, Dresher, PA (US); Matthew G. Laporte, Honeybrook, PA (US); and Susan R. Rippin, Wilmington, DE (US)
Assigned to MEDIVIR AB, Huddinge (SE)
Filed by Medivir AB, Huddinge (SE)
Filed on May 3, 2022, as Appl. No. 17/735,776.
Application 16/396,888 is a division of application No. 16/019,589, filed on Jun. 27, 2018, granted, now 10,314,881, issued on Jun. 11, 2019.
Application 14/075,190 is a division of application No. 13/611,274, filed on Sep. 12, 2012, granted, now 8,603,816, issued on Dec. 10, 2013.
Application 13/611,274 is a division of application No. 12/819,221, filed on Jun. 20, 2010, granted, now 8,283,372, issued on Oct. 9, 2012.
Application 17/735,776 is a continuation of application No. 16/783,481, filed on Feb. 6, 2020, granted, now 11,351,221.
Application 16/783,481 is a continuation of application No. 16/396,888, filed on Apr. 29, 2019, granted, now 10,596,220, issued on Mar. 24, 2020.
Application 16/019,589 is a continuation of application No. 15/344,813, filed on Nov. 7, 2016, granted, now 10,034,912, issued on Jul. 31, 2018.
Application 15/344,813 is a continuation of application No. 14/607,752, filed on Jan. 28, 2015, abandoned.
Application 14/607,752 is a continuation of application No. 14/075,190, filed on Nov. 8, 2013, granted, now 8,986,993, issued on Mar. 24, 2015.
Claims priority of provisional application 61/222,668, filed on Jul. 2, 2009.
Prior Publication US 2023/0149500 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/05 (2006.01); A61K 31/404 (2006.01); A61K 31/555 (2006.01); A61K 38/07 (2006.01); A61K 45/06 (2006.01); A61N 5/06 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07D 403/06 (2006.01); C07D 403/14 (2006.01); C07K 5/02 (2006.01); C07K 5/06 (2006.01); C07K 5/062 (2006.01); C12N 5/09 (2010.01); A61K 38/00 (2006.01)
CPC A61K 38/05 (2013.01) [A61K 31/404 (2013.01); A61K 31/555 (2013.01); A61K 38/07 (2013.01); A61K 45/06 (2013.01); A61N 5/062 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07D 403/06 (2013.01); C07D 403/14 (2013.01); C07K 5/02 (2013.01); C07K 5/06 (2013.01); C07K 5/06026 (2013.01); C12N 5/0693 (2013.01); A61K 38/00 (2013.01); C12N 2500/46 (2013.01); Y02P 20/55 (2015.11)] 17 Claims
 
1. A method of treating cancer in a mammal in need thereof, comprising administering to the mammal an effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
wherein R5 is —CH2CH3, or a pharmaceutically acceptable salt thereof, and
a second chemotherapy, wherein the second chemotherapy comprises a biological agent which binds to and activates a TRAIL receptor, azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, or tioguanine.